(S (NP (NP (JJ Adverse) (NN drug) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NNP ADR)) (-RRB- -RRB-))) (VP (VBZ is) (VP (ADVP (RB widely)) (VBN concerned) (PP (IN for) (NP (JJ public) (NN health) (NN issue))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT an) (JJ original) (NN approach)) (SBAR (S (VP (TO to) (VP (VB detect) (NP (DT the) (NNP ADRs)) (S (VP (VBG using) (NP (NP (NN feature) (NN matrix)) (CC and) (NP (NN feature) (NN selection))))))))))) (. .))
(S (NP (DT The) (NNS experiments)) (VP (VBP are) (VP (VBN carried) (PRT (IN out)) (PP (IN on) (NP (NP (DT the) (NN drug)) (NP (NNP Simvastatin)))))) (. .))
(S (S (NP (NP (JJ Major) (NN side) (NNS effects)) (PP (IN for) (NP (DT the) (NN drug)))) (VP (VBP are) (VP (VBN detected)))) (CC and) (S (NP (JJR better) (NN performance)) (VP (VBZ is) (VP (VBN achieved) (PP (VBN compared) (PP (TO to) (NP (JJ other) (JJ computerized) (NNS methods))))))) (. .))
(S (S (NP (DT The) (JJ detected) (NNP ADRs)) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (DT the) (JJ computerized) (NN method)))))) (, ,) (S (NP (JJ further) (NN investigation)) (VP (VBZ is) (VP (VBN needed)))) (. .))
